Director
Sarcoma Oncology Research Center
Dr. Sant P. Chawla is a world-renowned leader in the field of sarcoma oncology, dedicating his career to improving the lives of patients battling bone and soft-tissue sarcomas. His unwavering commitment to research and innovation has led to groundbreaking advancements in treatment options, offering hope and improved outcomes for countless patients.
Dr. Chawla is the Director of Sarcoma Oncology Center in Santa Monica, CA, where he leads clinical cancer research efforts and conducts groundbreaking clinical research in pancreatic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer, and gastrointestinal tumors.
Dr. Chawla's pioneering spirit has been evident throughout his distinguished career. In the 1980s, he played a pivotal role in developing limb-saving treatments for young osteosarcoma patients, offering an alternative to amputation, which was the only option previously.
Dr. Chawla's commitment to research has yielded significant results. He has conducted over 60 clinical trials, many of which have led to FDA and EMA approval of new cancer drugs. These include medications like carboplatin, trabectedin, pazopanib, eribulin, aprepitant, and denosumab, all playing a crucial role in the fight against cancer.
Most recently, Dr. Chawla's leadership at the Sarcoma Oncology Center led to a breakthrough Phase II trial for Aldoxorubicin. This trial demonstrated significantly increased progression-free and overall survival rates without cardiotoxicity, a major improvement over traditional anthracyclines.
